title: Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients.
abstract: The bactericidal activity of vancomycin and telavancin was compared against 4 clinical methicillin-resistant Staphylococcus aureus isolates recently recovered from cancer patients, using minimum bactericidal concentration (MBC):MIC ratios and time-kill studies. All 4 isolates were susceptible to both agents based on individual MIC values. The 2 methodologies for assessing bactericidal activity produced variable results. Telavancin appeared to have somewhat better bactericidal activity than vancomycin based on narrower MBC:MIC ratios. However, based on the results of the time-kill studies, neither agent demonstrated reliable bactericidal activity (defined as a ≥3 log10reduction of the starting inoculum at the end of 24hours) against these organisms. These findings might be of some therapeutic importance in certain clinical settings and/or specific patient populations (such as febrile neutropenic patients) in whom potent bactericidal activity is either desired or preferred.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Houston, College of Pharmacy, Houston, TX, USA. Electronic address: krolston@mdanderson.org.
authors.forename: Kenneth Vi
authors.initials: KV
authors.lastname: Rolston
authors.affiliation: The University of Houston, College of Pharmacy, Houston, TX, USA.
authors.forename: Weiqun
authors.initials: W
authors.lastname: Wang
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Lior
authors.initials: L
authors.lastname: Nesher
authors.affiliation: Wayne State University, Detroit, MI, USA.
authors.forename: Jordan R
authors.initials: JR
authors.lastname: Smith
authors.affiliation: Wayne State University, Detroit, MI, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rybak
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Houston, College of Pharmacy, Houston, TX, USA.
authors.forename: Randall A
authors.initials: RA
authors.lastname: Prince
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification*; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013997:Time Factors; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D014640:Vancomycin; C487637:telavancin
keywords: Bactericidal activity; Cancer patients; MRSA; Telavancin; Time-kill; Vancomycin